Population pharmacokinetics of tenofovir in AIDS patients. - Wikidata - wikimedia - TriplyDB

Population pharmacokinetics of tenofovir in AIDS patients.

Population pharmacokinetics of tenofovir in AIDS patients.

http://www.wikidata.org/entity/Q45349377

about

Pharmacokinetics and pharmacodynamics of the reverse transcriptase inhibitor tenofovir and prophylactic efficacy against HIV-1 infection Low body weight in females is a risk factor for increased tenofovir exposure and drug-related adverse events Can therapeutic drug monitoring improve pharmacotherapy of HIV infection in adolescents?Unsuccessful therapy with adefovir and entecavir-tenofovir in a patient with chronic hepatitis B infection with previous resistance to lamivudine: a fourteen-year evolution of hepatitis B virus mutations Plasma and intracellular population pharmacokinetic analysis of tenofovir in HIV-1-infected patients.Influence of ABCC2 and ABCC4 polymorphisms on tenofovir plasma concentrations in Thai HIV-infected patients Physiologically-based pharmacokinetic modeling of renally excreted antiretroviral drugs in pregnant women.Pharmacokinetic modelling of efavirenz, atazanavir, lamivudine and tenofovir in the female genital tract of HIV-infected pre-menopausal women.Biphasic elimination of tenofovir diphosphate and nonlinear pharmacokinetics of zidovudine triphosphate in a microdosing study Age-related differences in plasma and intracellular tenofovir concentrations in HIV-1-infected children, adolescents and adults Higher tenofovir exposure is associated with longitudinal declines in kidney function in women living with HIV.Clinical pharmacokinetics of antiretroviral drugs in older persons.Population Pharmacokinetics of Tenofovir in HIV-1-Uninfected Members of Serodiscordant Couples and Effect of Dose Reporting Methods.Estimation of tenofovir's population pharmacokinetic parameters without reliable dosing histories and application to tracing dosing history using simulation strategies.Population pharmacokinetics of tenofovir and tenofovir-diphosphate in healthy women.Common clinical conditions - age, low BMI, ritonavir use, mild renal impairment - affect tenofovir pharmacokinetics in a large cohort of HIV-infected women.Steady-state pharmacokinetics of tenofovir disoproxil fumarate in human immunodeficiency virus-infected Chinese patients.ABCC2*1C and plasma tenofovir concentration are correlated to decreased glomerular filtration rate in patients receiving a tenofovir-containing antiretroviral regimen.Tenofovir plasma concentrations in post-menopausal versus pre-menopausal HIV-infected women.Virologic failure in an HIV-infected woman given desogestrel for excessive menstrual bleeding.Pharmacogenetics-based population pharmacokinetic analysis of tenofovir in Thai HIV-infected patients.

P2860

Q28481276-9ABA147E-DD94-4BEA-AAAD-32A7F531F9E0 Q28535587-1C770BB9-B6F4-415A-B8A9-BC4635647D86 Q33914723-ADAF8588-A658-4CFB-A477-E6E0EEFC3AA9 Q33940140-389A5F53-AE15-497D-B7AC-D20171D64501 Q35363649-A9ED35BF-2689-4BC5-B913-6C2C77392DFB Q35607723-57CA0638-20FA-4BF6-AE5D-95EEAD38C020 Q36243626-AAEF5E06-47B3-4764-B726-B13A18E117C2 Q36430073-A9843E00-1A28-4D26-A19B-FFACCFA8597D Q36432228-EBBA777D-B36B-40E4-8893-D0E0BCCD31EA Q36650454-7CEE794F-B1BC-46F3-8E57-2CEA801D629F Q36663586-B6FCC617-30FE-475F-8489-6D574B12CEC7 Q36905884-55E63883-2E1B-4B79-BEC8-971EE448E713 Q37203867-671EAF06-0DC8-4AA8-815A-EFEAF5DEFAFD Q37210864-52829958-205F-4494-B965-08C0F6891E9C Q37224902-FF94DFDF-C0B4-46B4-89D3-A86E9A99B2B8 Q37641171-D8F5C0AA-680B-493B-AFE9-7AAF13275362 Q38798813-A8930870-4443-4BA7-92F7-BF00850511B6 Q42216997-BA331D90-7571-4651-A34A-D8EE6850AE74 Q42279687-FD25662F-7807-47F0-A3C0-B131AFC40FEB Q44185379-4253CB12-C80C-4EED-8B3A-683A7FF6F664 Q47633560-5E765657-09C2-4D02-9BDA-6A3584205BF7

P2860

Population pharmacokinetics of tenofovir in AIDS patients.

http://www.wikidata.org/entity/Q45349377

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh-hant

name

Population pharmacokinetics of tenofovir in AIDS patients.

@en

Population pharmacokinetics of tenofovir in AIDS patients.

@nl

type

label

Population pharmacokinetics of tenofovir in AIDS patients.

@en

Population pharmacokinetics of tenofovir in AIDS patients.

@nl

prefLabel

Population pharmacokinetics of tenofovir in AIDS patients.

@en

Population pharmacokinetics of tenofovir in AIDS patients.

@nl

P1433

Q45349377-6EA37B8E-77F5-46AE-A815-B2A13971069E

P1476

Q45349377-04D646EE-150D-4F2B-918B-DD121E741618

P2093

Q45349377-2988ED8E-9D91-497C-986E-D8A5E66E8DB8

Q45349377-3308B2F6-CC1A-41CF-8B9D-9C9EE397B47A

Q45349377-7AE582BC-424E-49C8-937C-83D2B139CA61

Q45349377-C44C6A59-8D07-474D-8B6A-FA429D4B782C

Q45349377-D33F1BAD-4631-4187-A953-B7D2C181AA4E

Q45349377-E6B7DAE5-62B4-49B4-9FD4-A39E072922FE

Q45349377-ECE44E4D-DD02-455F-B910-4BE68B4E964C

Q45349377-FB429744-DBD9-46AE-9D62-EAB572D59E6E

P2860

Q45349377-096B0C2E-4326-4E99-B940-E86600090840

Q45349377-0A273BF0-EB14-43AA-85EA-579F84EAB138

Q45349377-0B751516-7D04-43BC-A593-0D346195CFD1

Q45349377-21930AC0-9D17-42B3-8B73-B0148DB1CDDE

Q45349377-239093EB-D369-4749-AD22-4C4C739FDFD9

Q45349377-62E85ACF-F4FA-40FF-88FF-2A8E1423256E

Q45349377-752C8653-348A-4095-8D0C-3865C60B27B5

Q45349377-89BF6407-EF90-4FA5-8C00-B4043EE24C25

Q45349377-A053121E-23C7-4484-8430-419246AA2D40

Q45349377-A4A77856-E97C-475A-9832-6067A416513C

P304

Q45349377-22C3F279-B7C0-4111-86F7-3BD5E1A0A45D

P31

Q45349377-84914637-C3AA-4954-B554-9CE805F730E8

P356

Q45349377-CDED8445-7660-4ED7-A275-E4BF9F85116E

P433

Q45349377-C19A558E-CA86-4C82-AF8A-E7770FEBE506

P478

Q45349377-29E4FF3C-1420-43F7-8750-9392CAC9F84B

P577

Q45349377-E0EE1924-6121-4A7F-BA1E-123107807718

P698

Q45349377-1542D298-0A78-4899-A387-1304820228F5

P356

0091270008322908

P1433

The Journal of Clinical Pharmacology

P1476

Population pharmacokinetics of tenofovir in AIDS patients.

@en

P2093

André Boibieux

http://www.w3.org/2001/XMLSchema#string

Jean-Michel Livrozet

http://www.w3.org/2001/XMLSchema#string

Jérôme Guitton

http://www.w3.org/2001/XMLSchema#string

Laurent Cotte

http://www.w3.org/2001/XMLSchema#string

Marie-Claude Gagnieu

http://www.w3.org/2001/XMLSchema#string

Michel Tod

http://www.w3.org/2001/XMLSchema#string

Mirna El Barkil

http://www.w3.org/2001/XMLSchema#string

Patrick Miailhes

http://www.w3.org/2001/XMLSchema#string

P2860

Population pharmacokinetics of tenofovir in human immunodeficiency virus-infected patients taking highly active antiretroviral therapy.

Phase i/ii trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults.

Pharmacokinetics and dosing recommendations of tenofovir disoproxil fumarate in hepatic or renal impairment.

Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics.

Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions.

Intrapatient variability of efavirenz concentrations as a predictor of virologic response to antiretroviral therapy

Mechanism of active renal tubular efflux of tenofovir.

Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro.

The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients.

Evaluation of hypothesis testing for comparing two populations using NONMEM analysis.

P304

1282-1288

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/0091270008322908

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

48

http://www.w3.org/2001/XMLSchema#string

P577

2008-09-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18779377

http://www.w3.org/2001/XMLSchema#string